["alzheimer's disease"]
['t-817ma-h', 't-817ma-l', 'placebo']

        Inclusion Criteria:

          -  Male or female (post-menopausal or surgically sterile)

          -  Patients with Mild to moderate Alzheimer's disease who are receiving donepezil
             (Aricept®) or rivastigmine transdermal system (Exelon® Patch), . Memantine (Namenda®)
             is allowed only when prescribed in combination with donepezil or rivastigmine
             transdermal system.

          -  Age 55 to 85 inclusive

          -  Patients must be living in the community

          -  Patients must have an eligible informant or study partner (caregiver)

          -  Patients and eligible informant or study partner (caregiver) must be able to read and
             understand English.

          -  Informed consent obtained from both the patient and the caregiver

        Exclusion Criteria:

          -  Patients with clinically significant cardiac, hepatic or renal impairment

          -  Patient have a dementia not of the Alzheimer's type etc (According to the protocol)

          -  Patients who are taking any drug other than donepezil or rivastigmine transdermal
             system for Alzheimer's disease, including olal rivastigmine (Exelon®), galantamine
             (Razadyne®)
      